NEO 📈 NeoGenomics - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US64049M2098

NEO: Cancer, Testing, Laboratory, Services, Diagnostics, Molecular, Genetics

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida. Web URL: https://www.neogenomics.com

Additional Sources for NEO Stock

NEO Stock Overview

Market Cap in USD 2,276m
Sector Healthcare
Industry Diagnostics & Research
GiC Sub-Industry Life Sciences Tools & Services
IPO / Inception 1999-11-02

NEO Stock Ratings

Growth 5y -45.2%
Fundamental -26.8%
Dividend -
Rel. Strength Industry -386
Analysts 4.31/5
Fair Price Momentum 13.93 USD
Fair Price DCF -

NEO Dividends

No Dividends Paid

NEO Growth Ratios

Growth Correlation 3m 76.8%
Growth Correlation 12m 8.9%
Growth Correlation 5y -62.6%
CAGR 5y -11.25%
CAGR/Mean DD 5y -0.22
Sharpe Ratio 12m -0.30
Alpha -55.66
Beta 1.41
Volatility 47.76%
Current Volume 3306k
Average Volume 20d 765.3k
What is the price of NEO stocks?
As of December 21, 2024, the stock is trading at USD 16.41 with a total of 3,306,028 shares traded.
Over the past week, the price has changed by -7.45%, over one month by +6.84%, over three months by +0.80% and over the past year by -14.71%.
Is NeoGenomics a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, NeoGenomics (NASDAQ:NEO) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -26.81 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NEO as of December 2024 is 13.93. This means that NEO is currently overvalued and has a potential downside of -15.11%.
Is NEO a buy, sell or hold?
NeoGenomics has received a consensus analysts rating of 4.31. Therefor, it is recommend to buy NEO.
  • Strong Buy: 7
  • Buy: 3
  • Hold: 3
  • Sell: 0
  • Strong Sell: 0
What are the forecast for NEO stock price target?
According to ValueRays Forecast Model, NEO NeoGenomics will be worth about 15.4 in December 2025. The stock is currently trading at 16.41. This means that the stock has a potential downside of -5.91%.
Issuer Forecast Upside
Wallstreet Target Price 20.9 27.4%
Analysts Target Price 20.4 24.1%
ValueRay Target Price 15.4 -5.9%